Epstein Secrets

ts were higher overnight reversing some of yesterday's selloff, especially in Japan where the NKY225 hit its highest level since Sept 2008. Gains in Tokyo were yen-led after the current BOJ governor, Masaaki Shirakawa announced his intention to end his term 3 weeks early, on Mar 19th. This accelerates

proving 213 (trading +1.9%) • Syngenta FY EBITDA light, EPS slight better, revs in line, div better, conf call +ve for Q1 (trading -1.4%) • Elan: Biogen to Pay Elan $3.25bn for the full rights to Tysabri (trading +10%) • Nokian Renkaat O4 miss buy dividend increase, +ve conf call sees 2013 ENIT slig

2495; Hong Kong +852 2848-5989: Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169: Singapore +65 68346860: Sydney +61 (0)2.9770-1505; Tokyo +81 (0)16836.9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway. (Attention: Research Ma

s from Akebia Therapeutics Inc, Alexion Pharmaceuticals. Alnylam Pharmaceuticals, AMAG Pharmaceuticals. Inc., Amgen. Inc., Auxilium Pharmaceuticals, Biogen Idec Inc. Celgene Corp, Chimerix Inc. Cubist Pharmaceuticals Inc.. Gilead Sciences Inc.. GW Pharmaceuticals PLC. ImmunoGen Inc.. Incyte Corporation

2495; Hong Kong +852 2848-59S9: Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425.8169: Singapore +65 68346860: Sydney1.61 (0)2.9770-1505; Tokyo +81 (0)3.6836-9000. Mtematively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway. (Attention: Research Man

cl. Alzheimer's (2H14), Tysabri in SPMS (mid-2015), STX-100, Neublastin and Lupus. Guidance points to strong underlying growth for blz and stock — Biogen remains a top pick: Even without the AIFA benefit, guidance still incr. by -$1.30 or 11%. We've raised our 2014E/2015E EPS to $13.00/$16.28 from $